Frederick Lansigan, MD

Lindsay Rein, MD, and Frederick Lansigan, MD, detail other key data from ASH 2025 for non-advanced systemic mastocytosis and ongoing research to watch in the space.

Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional findings from the SUMMIT trial from ASH 2025 for bezuclastinib in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, discuss data from the SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, compare the profiles of the investigational agent bezuclastinib and the approved agent avapritinib in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, delve into the frequency of KIT D816V mutations in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, discuss current treatment standards for non-advanced systemic mastocytosis.